Patients Recruited for Phase 2 Study of Experimental Friedreich’s Ataxia Treatment
According to a press release from Barcelona-based biotechnology company Minoryx Therapeutics, the Company has completed enrollment for a phase 2 clinical study of its experimental Friedreich's ataxia treatment, MIN-102 (generic…